Letters to the Editor

Rituximab therapy after pediatric hematopoietic stem cell transplantation can cause prolonged B cell impairment and increases the risk for infections - a retrospective matched cohort study

Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Germany; The German Cancer Consortium (DKTK), Partner Site Berlin, Berlin, Germany; The German Cancer Research Center (DKFZ), Heidelberg
Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin
Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin
Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin
Institute of Biometry and Clinical Epidemiology, Charité - Universitätsmedizin Berlin, Berlin
Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin
Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Germany; The German Cancer Consortium (DKTK), Partner Site Berlin, Berlin, Germany; The German Cancer Research Center (DKFZ), Heidelberg
Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Germany; The German Cancer Consortium (DKTK), Partner Site Berlin, Berlin, Germany; The German Cancer Research Center (DKFZ), Heidelberg, Germany; Experimental and Clinical Research Center, Max Delbrück Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Berlin
Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Germany; The German Cancer Consortium (DKTK), Partner Site Berlin, Berlin, Germany; The German Cancer Research Center (DKFZ), Heidelberg
Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Department of Pediatrics, Helios Klinikum Berlin-Buch, Berlin
Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Germany; Deparment of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany; Labor Berlin - Charité Vivantes GmbH, Department of Immunology, Berlin, Germany; Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité - Universitätsmedizin Berlin, Berlin
Institute of Transfusion Medicine, Charité - Universitätsmedizin Berlin, Berlin
Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Germany; The German Cancer Consortium (DKTK), Partner Site Berlin, Berlin, Germany; The German Cancer Research Center (DKFZ), Heidelberg
Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin
Department of Hematology/Oncology and General Pediatrics, Children’s University Hospital, University of Tuebingen, Tuebingen
Department of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Germany; The German Cancer Consortium (DKTK), Partner Site Berlin, Berlin, Germany; The German Cancer Research Center (DKFZ), Heidelberg
Haematologica Early view Sep 22, 2022 https://doi.org/10.3324/haematol.2022.281134